Megakaryocyte (MK)

Megakaryocytes are large, polyploid myeloid cells primarily located in the bone marrow that serve as the specialized precursors for blood platelets [1, 7]. They differentiate from hematopoietic stem cells through a complex process called megakaryopoiesis, characterized by endomitosis—a unique cell cycle where DNA replicates without cytoplasmic division, leading to high nuclear ploidy and an expansive cytoplasm [7, 12]. The primary physiological regulator of this process is Thrombopoietin (TPO), which binds to its receptor, MPL, on the surface of megakaryocytes and their progenitors to drive cell growth, maturation, and eventual platelet fragmentation [11, 13]. In clinical medicine, megakaryocytes are the focal point of therapies for thrombocytopenia, where TPO receptor agonists are used to stimulate platelet production in conditions like immune thrombocytopenic purpura and chronic liver disease [5, 13]. Conversely, in myeloproliferative neoplasms such as essential thrombocythemia and primary myelofibrosis, overactive megakaryocyte signaling leads to pathological increases in platelets and a significant risk of bone marrow fibrosis or thrombosis [8, 12].

Other names

MKMegMyeloid megakaryocytePromegakaryocyte

Drugs primarily modulate this cell lineage through the agonism of the Thrombopoietin receptor (MPL), which activates JAK2/STAT and MAPK/ERK signaling pathways to promote megakaryocyte proliferation and differentiation [5, 13]. Other agents, such as anagrelide, inhibit phosphodiesterase 3 to interfere with megakaryocyte maturation and reduce platelet counts in myeloproliferative disorders, while anti-platelet drugs like aspirin affect megakaryocyte-derived cyclooxygenase enzymes to alter future platelet function [2, 12].